Topics

Millendo Therapeutics to Participate in May Investor Conferences

08:30 EDT 2 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews at the follo...

Other Sources for this Article

Millendo Investor Contact:
Stephanie Ascher
Stern Investor Relations
212-362-1200
stephanie.ascher@sternir.com

Millendo Media Contact:
Betsy Yates
MacDougall
781-235-3094
byates@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Millendo Therapeutics to Participate in May Investor Conferences"

Quick Search

Relevant Topic

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...